Table 3.
Adjusted Cox hazards regression models for specific opportunistic illnesses for patients who used combination antiretroviral therapy (N = 1878 individuals)
| Tuberculosis | Esophageal candidiasis | Cerebral Toxoplamosis | PCP | |
|---|---|---|---|---|
| (N = 30) | (N = 10) | (N = 12) | (N = 8) | |
| HR (CI) | HR (CI) | HR (CI) | HR (CI) | |
| Gender-Risk | ||||
| Women | Ref. | Ref. | Ref. | Ref. |
| Heterosexual men | 0.85 (0.38–1.88) | 0.15 (0.02–1.25) | 1.46 (0.39–5.43) | 0.81 (0.16–4.20) |
| MSM | 0.53 (1.89–1.58) | 0.25 (0.05–1.42) | 0.31 (0.05–2.00) | 0.59 (0.08–4.16) |
| Age (per year) | 1.02 (0.99–1.06) | 0.93 (0.86–1.02) | 0.91 (0.84–0.99) | 1.07 (1.00–1.14) |
| Race/ethnicity | ||||
| White | Ref. | Ref. | Ref. | Ref. |
| Non-white | 0.86 (0.39–1.88) | 2.10 (0.43–10.29) | 0.46 (0.14–1.51) | 1.26 (0.27–5.87) |
| Educational level | ||||
| 0–8 years | 2.08 (0.78–5.51) | 0.89 (0.19–4.12) | 1.22 (0.29–5.10) | 0.38 (0.07–2.03) |
| 9+ years | Ref. | Ref. | Ref. | Ref. |
| Nadir CD4+ T lymphocyte (per 100 cells/mm3) | 0.85 (0.63–1.15) | 0.73 (0.42–1.25) | 0.89 (0.59–1.33) | 1.25 (0.83–1.90) |
| Opportunistic illness at enrollment | 23.0 (9.60–55.2) | 13.6 (2.93–63.3) | 34.6 (8.50–141.4) | 21.5 (2.86–162.1) |
| Time under cART (per year) | 0.78 (0.63–0.97) | 0.55 (0.29–1.03) | 0.61 (0.39–0.96) | 0.60 (0.33–1.08) |
PCP Pneumocystis jiroveci pneumonia, HR hazard ratio, CI 95 % confidence interval, MSM men who have sex with men
Bold font implies statistically significant results assuming a 5 % significance threshold